• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑脊液β-突触核蛋白作为临床前阿尔茨海默病的突触生物标志物。

Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.

作者信息

Barba Lorenzo, Abu Rumeileh Samir, Bellomo Giovanni, Paolini Paoletti Federico, Halbgebauer Steffen, Oeckl Patrick, Steinacker Petra, Massa Federico, Gaetani Lorenzo, Parnetti Lucilla, Otto Markus

机构信息

Department of Neurology, University Hospital Halle, Halle (Saale), Germany.

Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

出版信息

J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):83-86. doi: 10.1136/jnnp-2022-329124. Epub 2022 Aug 9.

DOI:10.1136/jnnp-2022-329124
PMID:35944974
Abstract

INTRODUCTION

β-synuclein (β-syn) is a presynaptic protein, whose cerebrospinal fluid (CSF) levels are increased in patients with Alzheimer's diseases (AD) showing mild cognitive impairment (MCI) and dementia (dem). Here, we aimed to investigate CSF β-syn in subjects at different AD stages, including preclinical AD (pre-AD), and to compare its behaviour with another synaptic biomarker, α-synuclein (α-syn), and two biomarkers of neuro-axonal damage, namely neurofilament light chain protein (NfL) and total tau protein (t-tau).

METHODS

We measured β-syn, α-syn, t-tau and NfL in CSF of 75 patients with AD (pre-AD n=17, MCI-AD n=28, dem-AD n=30) and 35 controls (subjective memory complaints, SMC-Ctrl n=13, non-degenerative neurological disorders, Dis-Ctrl n=22).

RESULTS

CSF β-syn, α-syn, t-tau were significantly elevated in pre-AD patients compared with controls (p<0.0001, p=0.02 and p=0.0001, respectively), while NfL only increased in dem-AD (p=0.001). Pre-AD cases showed lower t-tau concentrations than MCI-AD (p=0.04) and dem-AD (p=0.01). CSF β-syn had the best diagnostic performance for the discrimination of pre-AD subjects from all controls (area under the curve, AUC=0.97) and from SMC-Ctrl subjects (AUC=0.99).

DISCUSSION

CSF β-syn increases in the whole AD continuum since the preclinical stage and represents a promising biomarker of synaptic damage in AD.

摘要

引言

β-突触核蛋白(β-syn)是一种突触前蛋白,在患有轻度认知障碍(MCI)和痴呆(dem)的阿尔茨海默病(AD)患者的脑脊液(CSF)中水平升高。在此,我们旨在研究不同AD阶段(包括临床前AD(pre-AD))受试者的脑脊液β-syn,并将其行为与另一种突触生物标志物α-突触核蛋白(α-syn)以及两种神经轴突损伤生物标志物,即神经丝轻链蛋白(NfL)和总tau蛋白(t-tau)进行比较。

方法

我们测量了75例AD患者(pre-AD n = 17,MCI-AD n = 28,dem-AD n = 30)和35名对照者(主观记忆主诉,SMC-Ctrl n = 13,非退行性神经系统疾病,Dis-Ctrl n = 22)脑脊液中的β-syn、α-syn、t-tau和NfL。

结果

与对照组相比,pre-AD患者脑脊液中的β-syn、α-syn、t-tau显著升高(分别为p < 0.0001、p = 0.02和p = 0.0001),而NfL仅在dem-AD中升高(p = 0.001)。Pre-AD病例的t-tau浓度低于MCI-AD(p = 0.04)和dem-AD(p = 0.01)。脑脊液β-syn在区分pre-AD受试者与所有对照者(曲线下面积,AUC = 0.97)以及与SMC-Ctrl受试者(AUC = 0.99)方面具有最佳诊断性能。

讨论

脑脊液β-syn从临床前阶段开始在整个AD病程中升高,是AD中突触损伤一个有前景的生物标志物。

相似文献

1
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.脑脊液β-突触核蛋白作为临床前阿尔茨海默病的突触生物标志物。
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):83-86. doi: 10.1136/jnnp-2022-329124. Epub 2022 Aug 9.
2
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.脑脊液突触生物标志物在路易体病 AT(N)-基于亚组中的应用。
Neurology. 2023 Jul 4;101(1):e50-e62. doi: 10.1212/WNL.0000000000207371. Epub 2023 May 15.
3
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.脑脊液 α-突触核蛋白提高了阿尔茨海默病中脑脊液 tau 和 Aβ 的诊断和预后性能。
Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29.
4
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.脑脊液脂肪酸结合蛋白 3、α-突触核蛋白与阿尔茨海默病核心生物标志物在路易体疾病和阿尔茨海默病痴呆中的差异作用。
Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
5
Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.脑脊液 α- 突触核蛋白测定有助于提高阿尔茨海默病所致轻度认知障碍的早期鉴别诊断。
J Neurochem. 2019 Jul;150(2):218-230. doi: 10.1111/jnc.14719. Epub 2019 Jul 8.
6
Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.在纵向随访的轻度认知障碍和阿尔茨海默病患者中,血浆载脂蛋白 E 水平。
Alzheimers Res Ther. 2022 Aug 24;14(1):115. doi: 10.1186/s13195-022-01058-9.
7
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.血浆神经调节素 1 作为阿尔茨海默病的突触生物标志物:一项发现队列研究。
Alzheimers Res Ther. 2022 May 23;14(1):71. doi: 10.1186/s13195-022-01014-7.
8
Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.血浆神经丝轻链作为主观认知下降和轻度认知障碍的阿尔茨海默病生物标志物。
J Neurol. 2022 Aug;269(8):4270-4280. doi: 10.1007/s00415-022-11055-5. Epub 2022 Mar 14.
9
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.非β-淀粉样蛋白/tau 脑脊液标志物可提示阿尔茨海默病的分期和进展。
Alzheimers Res Ther. 2018 Sep 25;10(1):98. doi: 10.1186/s13195-018-0426-3.
10
Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.阿尔茨海默病鉴别诊断中的脑脊液:在专科认知诊所中扩展生物标志物组合的临床效用。
Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3.

引用本文的文献

1
Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy.脑脊液和血浆中的磷酸化α-突触核蛋白不能反映突触核蛋白病。
NPJ Parkinsons Dis. 2025 Aug 7;11(1):232. doi: 10.1038/s41531-025-01086-w.
2
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer's disease and Parkinson's disease.共病理学对阿尔茨海默病和帕金森病脑脊液及血浆突触标志物SNAP25和VAMP2的影响。
Alzheimers Res Ther. 2025 May 22;17(1):115. doi: 10.1186/s13195-025-01762-2.
3
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's disease.
新型脑脊液β-突触核蛋白特异性检测可提示阿尔茨海默病早期突触退变。
Alzheimers Res Ther. 2025 Apr 14;17(1):81. doi: 10.1186/s13195-025-01716-8.
4
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.多发性硬化症中的脑脊液突触生物标志物与认知障碍
J Neurol. 2024 Dec 21;272(1):85. doi: 10.1007/s00415-024-12851-x.
5
Identification of Candidate Protein Biomarkers Associated with Domoic Acid Toxicosis in Cerebrospinal Fluid of California Sea Lions ().鉴定与加利福尼亚海狮()脑中的软骨藻酸中毒相关的候选蛋白生物标志物。
J Proteome Res. 2024 Jul 5;23(7):2419-2430. doi: 10.1021/acs.jproteome.4c00103. Epub 2024 May 28.
6
Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.在主观认知下降和轻度认知障碍中联合使用血浆磷酸化 tau181 和神经丝轻链的未来展望和临床适用性。
Sci Rep. 2024 May 17;14(1):11307. doi: 10.1038/s41598-024-61655-6.
7
Plasma β-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy.手术和辅助治疗恶性胶质瘤患者的血浆β-突触核蛋白、GFAP 和神经丝。
Ann Clin Transl Neurol. 2023 Oct;10(10):1924-1930. doi: 10.1002/acn3.51878. Epub 2023 Aug 23.
8
Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease.脑脊液α-突触核蛋白预测前驱期阿尔茨海默病患者发生精神病的效度
Front Neurol. 2023 May 24;14:1124145. doi: 10.3389/fneur.2023.1124145. eCollection 2023.
9
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.脑脊液突触生物标志物在路易体病 AT(N)-基于亚组中的应用。
Neurology. 2023 Jul 4;101(1):e50-e62. doi: 10.1212/WNL.0000000000207371. Epub 2023 May 15.
10
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.帕金森病伴轻度认知障碍患者的脑脊液神经化学特征及认知变化
NPJ Parkinsons Dis. 2023 Apr 24;9(1):68. doi: 10.1038/s41531-023-00509-w.